Fig. 6: Upregulation of oncogenic signaling pathways are associated with inactivation of RASSF10 and impaired survival of renal carcinoma patients. | Oncogene

Fig. 6: Upregulation of oncogenic signaling pathways are associated with inactivation of RASSF10 and impaired survival of renal carcinoma patients.

From: RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice

Fig. 6

RNA isolated from Rassf10−/− and Rassf10 wildtype mouse embryonic fibroblasts were analyzed on MoGene-2_0-stRNA microarrays. Upregulated hallmarks were identified by gene set enrichment analysis. Enrichment plot for a IL6-JAK-STAT3 and b KRAS signaling are depicted. c MYC and d VEGFA are significantly negatively correlated with RASSF10 expression in papillary cell carcinoma (TCGA data set). Mean expression of RASSF10 and e MYC or f VEGFA in renal papillary cell carcinoma was analyzed in the pan-cancer RNA-seq panel with Kaplan–Meier plotter [42] and survival probability was plotted for low RASSF10 and high MYC/VEGF (black) expressing and high RASSF10 and low MYC/VEGF (red) expressing samples. g In clear cell carcinoma MYC is significantly negatively associated with RASSF10 expression and h expression of CDH1 is positively correlated with RASSF10. Correlation analysis of expression data using R2 Genomics Analysis and Visualization Platform [71] from human primary renal carcinomas (log2 data, TCGA data set).

Back to article page